Fundamental and clinical studies on nasal aerosol therapy with gentamicin.

概要

論文の詳細を見る
The possibility of ototoxicity caused by gentamicin (GM) aerosol into the nasal cavity was evaluated by measuring its serum concentration. The maximum permissible concentration of a commercially available GM injection solution for nasal nebulizer therapy was 4%as determined by counting ciliary activity measured by a photoelectric method. Using this tolerable concentration, clinical evaluation of GM aerosol therapy for chronic sinusitis was also performed.According to the serum concentration of GM, ototoxicity via nasal mucosal absorption of nebulized 4%GM injection solution was not expected becaused of influx into tympanic cavity via the eustachian tube.From the data obtained by human paranasal mucosa cultured in RPMI-1640 medium, a relative low concentration, from 0.5 to 1 %, of a GM injection solution was recommended because of its solvent toxicity. On the other hand, a 4%preparation of GM powder dissolved in physiological saline solution was permissible.GM nebulizer therapy was clinically evaluated using 1 %GM injection solution. Chronic sinusitis without nasal polyp improved by 25%in terms of subjective and objective symptoms, and by 12.5%in terms of total judgement, X-ray examination showed 14.3%improvement. Sinusitis wity nasal polyp showed no improvement.
耳鼻咽喉科臨床学会の論文